

# Imfinzi® (durvalumab) (Intravenous)

Document Number: IC-0301

Last Review Date: 06/01/2023

Date of Origin: 05/30/2017

Dates Reviewed: 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 06/2020, 09/2020, 12/2020, 03/2021, 04/2021, 06/2021, 09/2021, 12/2021, 03/2022, 06/2022, 09/2022, 10/2022, 12/2022, 03/2023, 06/2023

## I. Length of Authorization <sup>Δ 1</sup>

Coverage will be provided for 6 months and may be renewed (unless otherwise specified).

- Non-Small Cell Lung Cancer (single agent use as consolidation therapy): Coverage will be provided for 6 months and may be renewed up to a maximum of 12 months of therapy.

## II. Dosing Limits

### A. Quantity Limit (max daily dose) [NDC Unit]:

- Imfinzi 120 mg/2.4 mL single-dose vial: 4 vials per 14 days
- Imfinzi 500 mg/10 mL single-dose vial: 2 vials per 14 days

### B. Max Units (per dose and over time) [HCPCS Unit]:

- NSCLC: 112 billable units (1,120 mg) every 14 days
- SCLC: 150 billable units (1,500 mg) every 21 days x 6 doses, then 150 billable units (1,500 mg) every 28 days
- Biliary Tract Cancers & Ampullary Adenocarcinoma: 150 billable units (1,500 mg) every 21 days x 8 doses, then 150 billable units (1,500 mg) every 28 days
- Hepatocellular Carcinoma: 150 billable units (1,500 mg) every 28 days
- Cervical Cancer: 150 billable units (1,500 mg) every 21 days x 4 doses, then 150 billable units (1,500 mg) every 28 days

## III. Initial Approval Criteria <sup>1</sup>

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

### Universal Criteria

- Patient has not received previous therapy with a programmed death (PD-1/PD-L1)-directed therapy (e.g., nivolumab, pembrolizumab, atezolizumab, avelumab, cemiplimab, dostarlimab, nivolumab/relatlimab-rmbw, etc.) unless otherwise specified <sup>Δ</sup>; **AND**

## Non-Small Cell Lung Cancer (NSCLC) † ‡ 1,3-5,16

- Patient has unresectable stage II-III disease; **AND**
  - Patient has a performance status (PS) of 0-1; **AND**
  - Used as a single agent as consolidation therapy; **AND**
  - Disease has not progressed after definitive concurrent chemoradiation; **OR**
- Patient has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**
  - Used as first-line therapy; **AND**
    - Used in one of the following:
      - Patients with tumors that are negative for actionable molecular biomarkers\* and PD-L1  $\geq$  1% to 49%
      - Patients with PS of 0-1 who have tumors that are negative for actionable molecular biomarkers\* and PD-L1 < 1%
      - Patients with PS of 0-1 who are positive for one of the following molecular mutations: EGFR exon 20, KRAS G12C, BRAF V600E, NTRK1/2/3 gene fusion, MET exon-14 skipping, RET rearrangement, or ERBB2 (HER2); **AND**
    - Used in combination with tremelimumab-actl, albumin-bound paclitaxel, and carboplatin; **OR**
    - Used in combination with tremelimumab-actl, pemetrexed, and either carboplatin or cisplatin for nonsquamous cell histology; **OR**
    - Used in combination with tremelimumab-actl, gemcitabine, and either carboplatin or cisplatin for squamous cell histology; **OR**
  - Used as subsequent therapy; **AND**
    - Used in one of the following:
      - Patients with PS of 0-1 who are positive for one of the following molecular mutations: BRAF V600E, NTRK1/2/3 gene fusion, MET exon-14 skipping, or RET rearrangement
      - Patients with PS of 0-1 who are positive for one of the following molecular mutations and received prior targeted therapy§: EGFR exon 19 deletion or exon 21 L858R tumors, EGFR S768I, L861Q, and/or G719X mutation, ALK rearrangement, or ROS1 rearrangement; **AND**
    - Used in combination with tremelimumab-actl, albumin-bound paclitaxel, and carboplatin; **OR**
    - Used in combination with tremelimumab-actl, pemetrexed, and either carboplatin or cisplatin for nonsquamous cell histology; **OR**

- Used in combination with tremelimumab-actl, gemcitabine, and either carboplatin or cisplatin for squamous cell histology; **OR**
- Used as continuation maintenance therapy in patients who have achieved a tumor response or stable disease following initial therapy; **AND**
  - Used as a single agent following a first-line regimen with durvalumab and tremelimumab-actl plus chemotherapy; **OR**
  - Used in combination with pemetrexed following a first-line regimen with durvalumab, tremelimumab-actl, pemetrexed and either carboplatin or cisplatin for nonsquamous cell histology

*\* Note: Actionable molecular genomic biomarkers include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping mutation, RET rearrangement, and ERBB2 (HER2). If there is insufficient issue to allow testing for all of EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2) repeat biopsy and/or plasma testing should be done. If these are not feasible, treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.*

### **Small Cell Lung Cancer (SCLC) † ‡ Ⓢ 1,3,7,8,10**

- Patient has extensive stage disease (ES-SCLC); **AND**
  - Used as first-line therapy in combination with etoposide and either carboplatin or cisplatin; **OR**
  - Used as single-agent maintenance therapy after initial therapy with etoposide and either carboplatin or cisplatin

### **Biliary Tract Cancers (Gallbladder Cancer or Intra-/Extra-Hepatic Cholangiocarcinoma) † ‡ Ⓢ 1,3,14**

- Used in combination with cisplatin and gemcitabine; **AND**
  - Used as primary treatment for unresectable, resected gross residual (R2), locally advanced, or metastatic disease; **OR**
  - Used for recurrent disease >6 months after surgery with curative intent and >6 months after completion of adjuvant therapy; **OR**
  - Used as subsequent treatment for progression on or after systemic treatment for unresectable, resected gross residual (R2), or metastatic disease; **OR**
  - Used as neoadjuvant therapy for resectable locally advanced disease (***\*\*NOTE: Only applies to Gallbladder Cancer***); **AND**
    - Patient has incidental finding of suspicious mass during surgery where hepatobiliary surgery expertise is unavailable; **OR**
    - Patient has incidental finding on pathologic review; **OR**
    - Patient has mass on imaging

### **Hepatocellular Carcinoma † ‡ Ⓢ 1,3,11,12,15**

- Used as first-line therapy as a single agent or in combination with tremelimumab-actl; **AND**
  - Patient has unresectable disease and is not a transplant candidate; **OR**
  - Patient has liver-confined disease that is inoperable by performance status, comorbidity, or with minimal or uncertain extrahepatic disease; **OR**
  - Patient has metastatic disease or extensive liver tumor burden

### Ampullary Adenocarcinoma ‡<sup>3</sup>

- Used as first-line therapy in combination with gemcitabine and cisplatin; **AND**
- Patient has good performance status (e.g., ECOG 0-1, with good biliary drainage and adequate nutritional intake); **AND**
- Patient has pancreatobiliary and mixed type disease; **AND**
  - Patient has unresectable localized disease; **OR**
  - Patient has stage IV resected ampullary cancer; **OR**
  - Patient has metastatic disease at initial presentation

### Cervical Cancer ‡<sup>3,17</sup>

- Patient has small cell neuroendocrine carcinoma of the cervix (NECC); **AND**
- Used as first-line or subsequent therapy (if not used previously as first-line therapy) for persistent, recurrent, or metastatic disease; **AND**
- Used in combination with etoposide **AND** either cisplatin or carboplatin

| <b>§ Genomic Aberration/Mutational Driver Targeted Therapies</b><br>(Note: not all inclusive, refer to guidelines for appropriate use)  |  |  |  |  |
|---|--|--|--|--|
| Sensitizing <i>EGFR</i> mutation-positive tumors  | <i>ALK</i> rearrangement-positive tumors   | <i>ROS1</i> rearrangement-positive tumors  | <i>BRAF</i> V600E-mutation positive tumors   | <i>NTRK1/2/3</i> gene fusion positive tumors   |
| <ul style="list-style-type: none"> <li>– Afatinib</li> <li>– Erlotinib</li> <li>– Dacomitinib</li> <li>– Gefitinib</li> <li>– Osimertinib</li> <li>– Amivantamab (<i>exon-20 insertion</i>)</li> <li>– Mobocertinib (<i>exon-20 insertion</i>)</li> </ul> | <ul style="list-style-type: none"> <li>– Alectinib</li> <li>– Brigatinib</li> <li>– Ceritinib</li> <li>– Crizotinib</li> <li>– Lorlatinib</li> </ul> | <ul style="list-style-type: none"> <li>– Ceritinib</li> <li>– Crizotinib</li> <li>– Entrectinib</li> <li>– Lorlatinib</li> </ul> | <ul style="list-style-type: none"> <li>– Dabrafenib ± trametinib</li> <li>– Vemurafenib</li> </ul> | <ul style="list-style-type: none"> <li>– Larotrectinib</li> <li>– Entrectinib</li> </ul>                                 |
| PD-L1 tumor expression ≥ 1%   | <i>MET</i> exon-14 skipping mutations  | <i>RET</i> rearrangement-positive tumors   | <i>KRAS</i> G12C mutation positive tumors  | <i>ERBB2 (HER2)</i> mutation positive tumors   |
| <ul style="list-style-type: none"> <li>– Pembrolizumab</li> <li>– Atezolizumab</li> <li>– Nivolumab + ipilimumab</li> <li>– Cemiplimab</li> </ul>   | <ul style="list-style-type: none"> <li>– Capmatinib</li> <li>– Crizotinib</li> <li>– Tepotinib</li> </ul>  | <ul style="list-style-type: none"> <li>– Selpercatinib</li> <li>– Cabozantinib</li> <li>– Pralsetinib</li> </ul>                 | <ul style="list-style-type: none"> <li>– Sotorasib</li> <li>– Adagrasib</li> </ul>                 | <ul style="list-style-type: none"> <li>– Fam-trastuzumab deruxtecan-nxki</li> <li>– Ado-trastuzumab emtansine</li> </ul> |

|                             |  |  |  |  |
|-----------------------------|--|--|--|--|
| - Tremelimumab + durvalumab |  |  |  |  |
|-----------------------------|--|--|--|--|

<sup>Δ</sup> Notes:

- Patients responding to therapy who relapse ≥ 6 months after discontinuation due to duration (i.e., receipt of 24 months of therapy) are eligible to re-initiate PD-directed therapy.
- Patients who complete adjuvant therapy and progress ≥ 6 months after discontinuation are eligible to re-initiate PD-directed therapy for metastatic disease.
- Patients whose tumors, upon re-biopsy, demonstrate a change in actionable mutation (e.g., MSS initial biopsy; MSI-H subsequent biopsy) may be eligible to re-initiate PD-directed therapy and will be evaluated on a case-by-case basis.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

#### IV. **Renewal Criteria** <sup>Δ 1,3</sup>

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe or life-threatening infusion-related reactions, immune-mediated adverse reactions (e.g., pneumonitis, hepatitis, colitis, endocrinopathies, nephritis with renal dysfunction, dermatology reactions, pancreatitis, etc.), complications of allogeneic hematopoietic stem cell transplantation (HCST), etc.; **AND**

#### **NSCLC (single-agent use as consolidation therapy)**

- Patient has not exceeded a maximum of 12 months of therapy

#### **Continuation Maintenance Therapy for NSCLC**

- *Refer to Section III for criteria*

#### **Hepatocellular Carcinoma**

- Cases for patients with HCC who use treatment as part of STRIDE and experience disease progression but who are clinically stable and still deriving clinical benefit will be reviewed on a case-by-case basis.

#### **Continuation Maintenance Therapy for SCLC**

- *Refer to Section III for criteria*

V. Dosage/Administration <sup>Δ 1,7,8,12,17,18</sup>

| Indication                                | Dose  |
|---|---|
| <p>Non-Small Cell Lung Cancer (NSCLC)</p> | <p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>Weight ≥30 kg: Administer 10 mg/kg intravenously every 14 days OR 1,500 mg intravenously every 28 days until disease progression or unacceptable toxicity</li> <li>Weight &lt;30 kg: Administer 10 mg/kg intravenously every 14 days until disease progression or unacceptable toxicity</li> <li><b><i>NOTE:</i></b> Use as consolidation therapy for unresectable stage II-III disease may continue up to a maximum of 12 months in patients without disease progression or unacceptable toxicity.</li> </ul> <p><u>In combination with Tremelimumab-actl* and Platinum-Based Chemotherapy§:</u></p> <ul style="list-style-type: none"> <li>Weight ≥30 kg: Administer 1,500 mg intravenously every 21 days x 5 cycles, followed by a maintenance dose of 1,500 mg every 28 days thereafter, until disease progression or unacceptable toxicity</li> <li>Weight &lt;30 kg: Administer 20 mg/kg intravenously every 21 days x 5 cycles, followed by a maintenance dose of 20 mg/kg every 28 days thereafter, until disease progression or unacceptable toxicity</li> </ul> <p><b><i>*Note:</i></b> Refer to the Prescribing Information for tremelimumab-actl dosing information</p> <p><b><i>§</i></b> If patients receive fewer than 4 cycles of platinum-based chemotherapy, the remaining cycles of Tremelimumab-actl (up to a total of 5) should be given after the platinum-based chemotherapy phase, in combination with IMFINZI, every 4 weeks.</p> |
| <p>Small Cell Lung Cancer (SCLC)</p>      | <p><u>Weight ≥30 kg:</u><br/>Administer 1,500 mg intravenously in combination with chemotherapy every 21 days x 4 cycles*, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p> <p><u>Weight &lt;30 kg:</u><br/>Administer 20 mg/kg intravenously in combination with chemotherapy every 21 days x 4 cycles*, followed by a maintenance dose of 10 mg/kg as a single agent every 14 days thereafter, until disease progression or unacceptable toxicity</p> <p><b><i>*Note:</i></b> Patients may receive up to 2 additional cycles in combination with chemotherapy based on response and tolerability after the initial 4 cycles (6 cycles of combination therapy in total) <sup>8</sup></p>  |
| <p>Hepatocellular Carcinoma</p>           | <p><u>Single agent:</u><br/>Administer 1,500 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</p>  |

|  |  |
|--|--|
|  | <p><b>STRIDE (Single Tremelimumab Regular Interval Durvalumab):</b></p> <ul style="list-style-type: none"> <li>Weight <math>\geq</math>30 kg: Administer 1,500 mg intravenously following a single dose of tremelimumab-actl* at Day 1 of Cycle 1, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</li> <li>Weight &lt;30 kg: Administer 20 mg/kg intravenously following a single dose of tremelimumab-actl* at Day 1 of Cycle 1, followed by a maintenance dose of 20 mg/kg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</li> </ul> <p><i>*Note: Refer to the Prescribing Information for tremelimumab-actl dosing information</i></p> |
| Biliary Tract Cancers  | <p><u>Weight &gt;30 kg:</u><br/>Administer 1,500 mg intravenously in combination with chemotherapy every 21 days for up to 8 cycles, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p> <p><u>Weight &lt;30 kg:</u><br/>Administer 20 mg/kg intravenously in combination with chemotherapy every 21 days for up to 8 cycles, followed by a maintenance dose of 20 mg/kg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p>  |
| Ampullary Adenocarcinoma   | Administer 1,500 mg intravenously in combination with gemcitabine and cisplatin every 21 days for up to 8 cycles, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity  |
| Cervical Cancer  | <p><u>Weight &gt;30 kg:</u><br/>Administer 1,500 mg intravenously in combination with chemotherapy every 21 days x 4 cycles, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p> <p><u>Weight &lt;30 kg:</u><br/>Administer 20 mg/kg intravenously in combination with chemotherapy every 21 days x 4 cycles, followed by a maintenance dose of 10 mg/kg as a single agent every 14 days thereafter, until disease progression or unacceptable toxicity</p>  |
| <p><u>Dosing should be calculated using actual body weight and not flat dosing (as applicable) based on the following:</u></p> <ul style="list-style-type: none"> <li>Patient weight &gt; 30 kg and &lt;75 kg: Use 20 mg/kg dosing</li> </ul> <p><i>Note: This information is not meant to replace clinical decision making when initiating or modifying medication therapy and should only be used as a guide. Patient-specific variables should be taken into account.</i></p> |  |



## VI. Billing Code/Availability Information

### HCP/PCS Code:

- J9173 – Injection, durvalumab, 10 mg; 1 billable unit = 10 mg

### NDC(s):

- Imfinzi 120 mg/2.4 mL single-dose vial: 00310-4500-xx
- Imfinzi 500 mg/10 mL single-dose vial: 00310-4611-xx

## VII. References

1. Imfinzi [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; November 2022. Accessed May 2023.
2. Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. *J Clin Oncol*. 2016 Sep 10;34(26):3119-25.
3. Referenced with permission from the NCCN Drugs and Biologics Compendium (NCCN Compendium®) durvalumab. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2023.
4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017 Sep 8.
5. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Non-Small Cell Lung Cancer. Version 3.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2023.
6. Gupta S, Sonpavde G, Grivas P, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). *J Clin Oncol*. 2019 Mar 1;37(7\_suppl):451.
7. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019 Nov 23;394(10212):1929-1939. Doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
8. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Small Cell Lung Cancer. Version 3.2023. National Comprehensive Cancer



Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2023.

9. Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase ½ Open-label Study. *JAMA Oncol.* 2017 Sep 14;3(9):e172411. Doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.
10. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol.* 2021 Jan;22(1):51-65. Doi: 10.1016/S1470-2045(20)30539-8.
11. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Hepatocellular Carcinoma. Version 1.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2023.
12. Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. *Journal of Clinical Oncology* 2022 40:4\_suppl, 379-379.
13. Govindan R, Aggarwal C, Antonia SJ, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. *Journal for ImmunoTherapy of Cancer* 2022;10:e003956. Doi: 10.1136/jitc-2021-003956.
14. Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. *J Clin Oncol.* 2022 Feb 1;40(4\_suppl):378-378.
15. Abou-Alfa GK, Chan SL, Furuse J, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. *Journal of Clinical Oncology* 36, no. 15\_suppl. DOI: 10.1200/JCO.2018.36.15\_suppl.TPS4144.
16. Johnson ML, Cho BC, Luft A, et al; POSEIDON investigators. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for

Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. *J Clin Oncol*. 2022 Nov 3;JCO2200975. doi: 10.1200/JCO.22.00975.

17. Paz-Ares L, Dvorkin M, Chen Y, et al; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6.
18. Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. *NEJM Evidence* 2022; 1:EVIDoa2200015. Available at <https://doi.org/10.1056/EVIDoa2200015>.

## Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description   |
|--------|--|
| C22.0  | Liver cell carcinoma   |
| C22.1  | Intrahepatic bile duct carcinoma   |
| C22.8  | Malignant neoplasm of liver, primary, unspecified as to type             |
| C22.9  | Malignant neoplasm of liver, not specified as primary or secondary       |
| C23    | Malignant neoplasm of gallbladder  |
| C24.0  | Malignant neoplasm of other and unspecified parts of biliary tract       |
| C24.1  | Malignant neoplasm of ampulla of Vater                                   |
| C24.8  | Malignant neoplasm of overlapping sites of biliary tract                 |
| C24.9  | Malignant neoplasm of biliary tract, unspecified                         |
| C33    | Malignant neoplasm of trachea  |
| C34.00 | Malignant neoplasm of unspecified main bronchus                          |
| C34.01 | Malignant neoplasm of right main bronchus                                |
| C34.02 | Malignant neoplasm of left main bronchus                                 |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung           |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung                 |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung                  |
| C34.2  | Malignant neoplasm of middle lobe, bronchus or lung                      |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung           |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung                 |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung                  |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung       |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung        |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung   |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung         |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung          |

| ICD-10  | ICD-10 Description  |
|---------|---|
| C53.0   | Malignant neoplasm of endocervix                                  |
| C53.1   | Malignant neoplasm of exocervix                                   |
| C53.8   | Malignant neoplasm of overlapping sites of cervix uteri           |
| C53.9   | Malignant neoplasm of cervix uteri, unspecified                   |
| C7A.1   | Malignant poorly differentiated neuroendocrine tumors             |
| C78.00  | Secondary malignant neoplasm of unspecified lung                  |
| C78.01  | Secondary malignant neoplasm of right lung                        |
| C78.02  | Secondary malignant neoplasm of left lung                         |
| C79.31  | Secondary malignant neoplasm of brain                             |
| C79.51  | Secondary malignant neoplasm of bone                              |
| C79.52  | Secondary malignant neoplasm of bone marrow                       |
| Z85.09  | Personal history of malignant neoplasm of other digestive organs  |
| Z85.118 | Personal history of other malignant neoplasm of bronchus and lung |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |   |   |
|---|---|---|
| Jurisdiction  | Applicable State/US Territory   | Contractor  |
| E (1)   | CA, HI, NV, AS, GU, CNMI  | Noridian Healthcare Solutions, LLC                |
| F (2 & 3)   | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ  | Noridian Healthcare Solutions, LLC                |
| 5   | KS, NE, IA, MO  | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6   | MN, WI, IL  | National Government Services, Inc. (NGS)          |
| H (4 & 7)   | LA, AR, MS, TX, OK, CO, NM  | Novitas Solutions, Inc.                           |
| 8   | MI, IN  | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)   | FL, PR, VI  | First Coast Service Options, Inc.                 |
| J (10)  | TN, GA, AL  | Palmetto GBA, LLC                                 |
| M (11)  | NC, SC, WV, VA (excluding below)  | Palmetto GBA, LLC                                 |
| L (12)  | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                           |

**Medicare Part B Administrative Contractor (MAC) Jurisdictions**

| <b>Jurisdiction</b> | <b>Applicable State/US Territory</b> | <b>Contractor</b>                        |
|---------------------|--------------------------------------|--|
| K (13 & 14)         | NY, CT, MA, RI, VT, ME, NH           | National Government Services, Inc. (NGS) |
| 15                  | KY, OH                               | CGS Administrators, LLC                  |